Modelling glioblastoma resistance to temozolomide. A mathematical model to simulate cellular adaptation in vitro

被引:1
|
作者
Pérez-Aliacar, Marina [1 ,2 ]
Ayensa-Jiménez, Jacobo [2 ,3 ]
Ranđelović, Teodora [3 ,4 ]
Ochoa, Ignacio [2 ,3 ,4 ]
Doblaré, Manuel [2 ,3 ,4 ,5 ]
机构
[1] Mechanical Engineering Department, School of Engineering and Architecture, University of Zaragoza, C/ Maria de Luna, Zaragoza,50018, Spain
[2] Engineering Research Institute of Aragón (I3A), University of Zaragoza, C/ Mariano Esquillor, Zaragoza,50018, Spain
[3] Institute for Health Research Aragón (IIS Aragón), Avda. San Juan Bosco, Zaragoza,50009, Spain
[4] Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Spain
[5] Nanjing Tech University, China
关键词
Chemotherapy - Diagnosis - Diseases - Patient monitoring - Sensitivity analysis;
D O I
10.1016/j.compbiomed.2024.108866
中图分类号
学科分类号
摘要
Drug resistance is one of the biggest challenges in the fight against cancer. In particular, in the case of glioblastoma, the most lethal brain tumour, resistance to temozolomide (the standard of care drug for chemotherapy in this tumour) is one of the main reasons behind treatment failure and hence responsible for the poor prognosis of patients diagnosed with this disease. In this work, we combine the power of three-dimensional in vitro experiments of treated glioblastoma spheroids with mathematical models of tumour evolution and adaptation. We use a novel approach based on internal variables for modelling the acquisition of resistance to temozolomide that was observed in experiments for a group of treated spheroids. These internal variables describe the cell's phenotypic state, which depends on the history of drug exposure and affects cell behaviour. We use model selection to determine the most parsimonious model and calibrate it to reproduce the experimental data, obtaining a high level of agreement between the in vitro and in silico outcomes. A sensitivity analysis is carried out to investigate the impact of each model parameter in the predictions. More importantly, we show how the model is useful for answering biological questions, such as what is the intrinsic adaptation mechanism, or for separating the sensitive and resistant populations. We conclude that the proposed in silico framework, in combination with experiments, can be useful to improve our understanding of the mechanisms behind drug resistance in glioblastoma and to eventually set some guidelines for the design of new treatment schemes. © 2024
引用
收藏
相关论文
共 43 条
  • [1] Design of Treatments for Overcoming Drug Resistance in Glioblastoma Cultures with a Mathematical Model of Cellular Adaptation
    Perez-Aliacar, Marina
    Ayensa-Jimenez, Jacobo
    Doblare, Manuel
    COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING II, CMBBE 2023, 2024, 39 : 253 - 262
  • [2] CHARACTERIZATION OF A MODEL OF TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA
    Bering, Elizabeth
    Yuan, Alice
    Cairncross, J.
    Blough, Michael
    NEURO-ONCOLOGY, 2018, 20 : 76 - 76
  • [3] ROLE OF CELLULAR PRION PROTEIN IN TEMOZOLOMIDE RESISTANCE OF GLIOBLASTOMA STEM CELLS
    Iglesia, Rebeca
    Prado, Mariana
    Alves, Rodrigo
    Tiek, Deanna
    Goenka, Anshika
    Song, Xiao
    Hu, Bo
    Hu, Bo
    Lopes, Marilene
    NEURO-ONCOLOGY, 2022, 24 : 35 - 35
  • [4] A glioblastoma and blood-brain barrier in vitro model to assess the tumor microenvironment and temozolomide resistance
    Lam, Maxine S.
    Aw, Joey
    Tan, Damien
    Vijayakumar, Ragavi
    Gordon, Khloe S.
    Birnbaum, Michael E.
    Sobota, Radoslaw M.
    Adriani, Giulia
    Pavesi, Andrea
    CANCER RESEARCH, 2023, 83 (07)
  • [5] A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia
    Musah-Eroje, Ahmed
    Watson, Sue
    JOURNAL OF NEURO-ONCOLOGY, 2019, 142 (02) : 231 - 240
  • [6] A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia
    Ahmed Musah-Eroje
    Sue Watson
    Journal of Neuro-Oncology, 2019, 142 : 231 - 240
  • [7] Ellagic Acid Enhances Antitumor Efficacy of Temozolomide in an in vitro Glioblastoma Model
    Cetin, Abdurrahman
    Biltekin, Burcu
    TURKISH NEUROSURGERY, 2020, 30 (06) : 813 - 821
  • [8] Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell Lines
    Zhu, Yuan
    Chen, Zhen
    Kim, Su Na
    Gan, Chao
    Ryl, Tatsiana
    Lesjak, Michaela Silvia
    Rodemerk, Jan
    Zhong, Rong De
    Wrede, Karsten
    Dammann, Philipp
    Sure, Ulrich
    CANCERS, 2022, 14 (09)
  • [9] Exploring Pathways Involved in Temozolomide Resistance in Glioblastoma: A Comparison of in Vitro Models and Patient Samples
    Karasayar, A. Dur
    Kala, E.
    Caylak, G.
    Inan, M.
    Onder, T.
    Kulac, I.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (11): : S10 - S10
  • [10] Translesion DNA Polymerases in Temozolomide Resistance: Cytotoxic and Antiproliferative Analysis in Glioblastoma Spheroids in vitro
    Ribeiro, Diego L.
    Latancia, Marcela T.
    Mendes, Davi
    Rocha, Clarissa R. R.
    Menck, Carlos F. M.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2022, 63 : 103 - 103